• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $ALGS

    Aligos Therapeutics Inc.

    Subscribe to $ALGS
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a synthetic oligonucleotide that is in Phase I clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company is also developing ALG-020572, an antisense oligonucleotide to decrease HBsAg levels; and ALG-055009, a small molecule THR-ß agonist for the treatment of non-alcoholic steatohepatitis. In addition, it is developing siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. The company has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting SARS-CoV-2; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

    IPO Year: 2020

    Exchange: NASDAQ

    Website: aligos.com

    Recent Analyst Ratings for Aligos Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    8/19/2024$75.00Buy
    H.C. Wainwright
    1/6/2023$2.00 → $3.00Neutral → Overweight
    Piper Sandler
    1/6/2023$2.50 → $3.00Hold → Buy
    Jefferies
    3/23/2022$15.00 → $4.00Overweight → Neutral
    Piper Sandler
    3/11/2022$47.00 → $15.00Overweight
    Piper Sandler
    3/11/2022$10.00 → $11.00Outperform
    SVB Leerink
    2/16/2022$15.00 → $10.00Outperform
    SVB Leerink
    1/7/2022$30.00 → $12.00Overweight → Neutral
    JP Morgan
    1/7/2022$29.00 → $15.00Outperform
    SVB Leerink
    1/6/2022Buy → Hold
    Jefferies
    See more ratings

    Aligos Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aligos Therapeutics Presents Positive Data at the EASL Congress 2025

      SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from eight presentations at the European Association for the Study of the Liver (EASL) Congress 2025, being held May 7 – 10, 2025 in Amsterdam, Netherlands. "We are pleased to have eight presentations at this year's EASL Congress from programs across our pipeline," stated Lawrence Blatt, PhD, MBA, Chairman, President, & CEO of Aligos Therapeutics. "In particular, we are excited to share an update on the 96-week data f

      5/8/25 8:00:00 AM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results

      SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the first quarter 2025. "We continued to make progress towards our corporate development plans aimed at advancing life-saving therapies for viral and liver diseases," stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer of Aligos Therapeutics. "Over the past few months, we raised over $100M to begin our important Phase 2 study of ALG-000184 i

      5/6/25 8:00:00 AM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025

      SOUTH SAN FRANCISCO, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company's first quarter 2025 financial results on Tuesday, May 6, 2025, before the open of the U.S. financial markets. About Aligos Aligos Therapeutics, Inc. (NASDAQ:ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D

      4/29/25 8:30:00 AM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025

      SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced eight abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2025, being held May 7 – 10, 2025 in Amsterdam, Netherlands. The abstracts released today can be found on the EASL website at https://www.easlcongress.eu/. Details on the abstracts are as follows: ALG-000184: Potential first-/best-in-class small molecule CAM-E for chronic hepatitis B virus (H

      4/23/25 4:05:00 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aligos Therapeutics Presents Positive Data at APASL 2025

      SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from three oral presentations at the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL) 2025, being held March 26 - 30, 2025 in Beijing, China. "We are pleased to present preliminary data out to 96 weeks in our Phase 1 study of ALG-000184, which continues to demonstrate first-/best-in-class reductions in important HBV markers," stated Lawrence Blatt, PhD, MBA, Chairma

      3/26/25 8:00:00 AM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      SOUTH SAN FRANCISCO, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos", "Company")), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase an aggregate of 4,000 shares of the Company's stock (the "Inducement Grant") to a newly hired employee on March 11, 2025 (the "Grant Date"), in connection with the commencement of employment. The Inducement Grant was granted pursuant to Aligos' 2024 Inducement Plan (the "Plan") as an inducemen

      3/14/25 8:00:00 AM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results

      SOUTH SAN FRANCISCO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the fourth quarter and full year 2024. "2024 was a pivotal year for the company, paving the way for the future of Aligos," stated Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer of Aligos Therapeutics. "That future looks bright as we move ALG-000184 closer towards a Phase 2 clinical study, which is expected to begin in mid-2025. We continue to b

      3/10/25 8:00:00 AM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025

      SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company's fourth quarter 2024 financial results on Monday, March 10, 2025, before the open of the U.S. financial markets. About Aligos Aligos Therapeutics, Inc. (NASDAQ:ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R

      3/3/25 8:00:00 AM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aligos Therapeutics Announces $105 Million Private Placement Financing

      Proceeds expected to fund the start of the ALG-000184 Phase 2 clinical study Funding expected to extend cash runway into the second half of 2026 SOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos", "Company")), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $105 million, before deducting placement agents' fees and other expenses. The private placement is being led by a life s

      2/12/25 7:00:00 AM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      SOUTH SAN FRANCISCO, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos", "Company")), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase an aggregate of 5,500 shares of the Company's stock (the "Inducement Grant") to a newly hired employee on December 10, 2024 (the "Grant Date"), in connection with the commencement of employment. The Inducement Grant was granted pursuant to Aligos' 2024 Inducement Plan (the "Plan") as an inducem

      12/13/24 8:00:00 AM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Aligos Therapeutics Inc. Financials

    Live finance-specific insights

    See more
    • Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH

      ALG-055009 dose groups met the primary endpoint with statistically significant reductions in liver fat at Week 12 as measured by MRI-PDFFPlacebo-adjusted median relative reductions in liver fat were up to 46.2% with a clear dose responseALG-055009 was well-tolerated with no serious adverse events or dose reductions. Importantly, ALG-055009 dose groups had a similar incidence of gastrointestinal-related adverse events with less diarrhea compared to placeboSignificant reductions in atherogenic lipids, including LDL-C, lipoprotein (a), and apolipoprotein B were observedConference call scheduled for 8:30am ET/5:30am PT today SOUTH SAN FRANCISCO, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Alig

      9/19/24 8:00:00 AM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024

      SOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos", "Company"))), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Company will share the topline results from the Phase 2a HERALD study of ALG-055009, a thyroid hormone receptor beta (THR-β) agonist, in metabolic-dysfunction associated steatohepatitis (MASH) subjects on Thursday, September 19, 2024 prior to the market open. Following the announcement, the Company will host a conference call and webcast at 8:30am ET/5:30am PT. Conference Call & Webcast Details Th

      9/18/24 5:00:00 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aligos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights

      CAM (ALG-000184) continues to demonstrate best in class potential in Phase 1bASO (ALG-020572) completed dosing in Phase 1a (HVs); Phase 1b study (CHB) initiated – 1st cohort fully enrolledsiRNA (ALG-125755) progressing on track through Phase 1 enabling nonclinical studiesTHR-β (ALG-055009) currently dosing in healthy volunteers and subjects with hyperlipidemiaMultiple COVID-19 3CL protease inhibitor drug candidates without need for ritonavir boosting identified – all more potent than nirmatrelvirMerck expanded the NASH research collaboration utilizing Aligos' proprietary oligonucleotide technology Cash, cash equivalents and investments of $205.8 million as of December 31, 2021 A sufficient

      3/10/22 4:05:00 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Aligos Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Aligos Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Aligos Therapeutics with a rating of Buy and set a new price target of $75.00

      8/19/24 6:51:07 AM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aligos Therapeutics upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Aligos Therapeutics from Neutral to Overweight and set a new price target of $3.00 from $2.00 previously

      1/6/23 9:05:04 AM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aligos Therapeutics upgraded by Jefferies with a new price target

      Jefferies upgraded Aligos Therapeutics from Hold to Buy and set a new price target of $3.00 from $2.50 previously

      1/6/23 9:03:03 AM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aligos Therapeutics downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Aligos Therapeutics from Overweight to Neutral and set a new price target of $4.00 from $15.00 previously

      3/23/22 7:05:03 AM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Piper Sandler reiterated coverage on Aligos Therapeutics with a new price target

      Piper Sandler reiterated coverage of Aligos Therapeutics with a rating of Overweight and set a new price target of $15.00 from $47.00 previously

      3/11/22 10:16:49 AM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVB Leerink reiterated coverage on Aligos Therapeutics with a new price target

      SVB Leerink reiterated coverage of Aligos Therapeutics with a rating of Outperform and set a new price target of $11.00 from $10.00 previously

      3/11/22 6:32:07 AM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVB Leerink reiterated coverage on Aligos Therapeutics with a new price target

      SVB Leerink reiterated coverage of Aligos Therapeutics with a rating of Outperform and set a new price target of $10.00 from $15.00 previously

      2/16/22 5:10:01 AM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aligos Therapeutics downgraded by JP Morgan with a new price target

      JP Morgan downgraded Aligos Therapeutics from Overweight to Neutral and set a new price target of $12.00 from $30.00 previously

      1/7/22 5:06:08 AM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVB Leerink reiterated coverage on Aligos Therapeutics with a new price target

      SVB Leerink reiterated coverage of Aligos Therapeutics with a rating of Outperform and set a new price target of $15.00 from $29.00 previously

      1/7/22 4:32:38 AM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aligos Therapeutics downgraded by Jefferies

      Jefferies downgraded Aligos Therapeutics from Buy to Hold

      1/6/22 2:10:22 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Aligos Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Aligos Therapeutics Appoints David Perry as Vice President of Business Development

      SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of David Perry as Vice President of Business Development, effective immediately. "We are pleased to welcome David to the Aligos team during this exciting time for the company," said Lesley Ann Calhoun, Executive Vice President and Chief Financial Officer at Aligos. "David's expertise in leading valuable partnerships will be instrumental as we strategically look to maximize the potential of our best-in-class pipeline

      10/1/24 8:00:00 AM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

      SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a

      9/24/24 8:00:00 AM ET
      $ALGS
      $HAE
      $NVO
      $PLRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical/Dental Instruments
      Biotechnology: Pharmaceutical Preparations
    • Aligos Therapeutics Strengthens Board with Two New Independent Directors

      SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) --  Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos", the "Company"))), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced the appointment of Heather Preston, M.D. and Margarita Chavez, J.D. as Class II Independent Directors to the Board of Directors, effective August 7, 2024. Dr. Preston will join the Nominating and Corporate Governance Committee as Chair and Ms. Chavez will join the Audit Committee. "We are pleased to announce the appointment of Dr. Heather Preston and Margarita Chavez to our Board of Directors," stated

      8/8/24 4:05:00 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath's Board of Directors

      Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company's Board of Directors effective May 23, 2024. "We are pleased to welcome Dr. Martell to the Delcath Board," said John Sylvester, Chairman of the Delcath Board of Directors. "Dr. Martell's extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be a great asset to Delcath as we strive to achieve our mission of improving pa

      5/28/24 9:30:00 AM ET
      $ACHV
      $ALGS
      $DCTH
      $PNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Medical/Dental Instruments
    • Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments

      Jordyn Tarazi joins as Vice President, Investor Relations and Corporate Communications Nikhil Aneja, CPA, CA appointed as Vice President, Finance SOUTH SAN FRANCISCO, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS) ("Aligos"), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced the appointments of Jordyn Tarazi as Vice President, Investor Relations and Corporate Communications and Nikhil Aneja as Vice President, Finance, effective immediately. "We are delighted to welcome Jordyn and Nikhil to the team," said Lesley Ann Calhoun, Executive Vice Presi

      2/13/24 8:00:00 AM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aligos Therapeutics Appoints Bridget Martell, MA, M.D., to its Board of Directors

      SOUTH SAN FRANCISCO, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company has appointed Bridget Martell, MA, M.D., to the Company's board of directors. "We are pleased to welcome Dr. Martell to our board of directors. Her decades of experience in therapeutics development and leadership in biotechnology will be invaluable to the company as we continue to move our therapeutic candidates, including those for chronic hepatitis B and NASH, through the clinic," said Lawrence Blatt, Ph.D., MB

      11/18/21 4:05:00 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aligos Therapeutics Appoints James Scopa, J.D., MBA, to its Board of Directors

      SOUTH SAN FRANCISCO, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company has appointed James Scopa, J.D., MBA, to the Company's board of directors. "We are thrilled to add someone of Jim's experience and accomplishments to Aligos' board, as the company continues its arc from its earliest, private, preclinical phase to growing into its role as an established clinical-stage public biopharma company," said Aligos Chief Executive Officer Lawrence Blatt, Ph.D., MBA. "Aligos will look to J

      4/27/21 4:01:00 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Aligos Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Aligos Therapeutics Inc.

      SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)

      11/14/24 6:57:50 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Aligos Therapeutics Inc.

      SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)

      11/14/24 6:19:11 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Aligos Therapeutics Inc.

      SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)

      11/14/24 5:03:16 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Aligos Therapeutics Inc.

      SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)

      11/14/24 4:37:46 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Aligos Therapeutics Inc.

      SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)

      11/14/24 4:34:49 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Aligos Therapeutics Inc.

      SC 13G - Aligos Therapeutics, Inc. (0001799448) (Subject)

      11/12/24 9:31:31 AM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Aligos Therapeutics Inc.

      SC 13G - Aligos Therapeutics, Inc. (0001799448) (Subject)

      9/12/24 4:21:40 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Aligos Therapeutics Inc. (Amendment)

      SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)

      2/14/24 5:07:18 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Aligos Therapeutics Inc. (Amendment)

      SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)

      2/14/24 4:37:13 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Aligos Therapeutics Inc. (Amendment)

      SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)

      2/14/24 4:21:51 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Aligos Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by President and CEO Blatt Lawrence

      4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)

      3/4/25 4:33:51 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Officer Symons Julian A.

      4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)

      3/4/25 4:33:20 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Officer Calhoun Lesley Ann

      4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)

      3/4/25 4:32:51 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Achneck Hardean

      4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)

      10/10/24 4:16:11 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Achneck Hardean

      3 - Aligos Therapeutics, Inc. (0001799448) (Issuer)

      9/26/24 4:15:28 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Calhoun Lesley Ann

      4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)

      9/6/24 4:23:49 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Blatt Lawrence

      4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)

      9/6/24 4:23:18 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Officer Symons Julian A.

      4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)

      9/6/24 4:22:44 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Chavez Margarita

      4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)

      8/9/24 4:09:21 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Preston Heather

      4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)

      8/9/24 4:08:56 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Aligos Therapeutics Inc. SEC Filings

    See more
    • SEC Form 10-Q filed by Aligos Therapeutics Inc.

      10-Q - Aligos Therapeutics, Inc. (0001799448) (Filer)

      5/6/25 8:14:10 AM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aligos Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Aligos Therapeutics, Inc. (0001799448) (Filer)

      5/6/25 8:00:34 AM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Aligos Therapeutics Inc.

      DEFA14A - Aligos Therapeutics, Inc. (0001799448) (Filer)

      4/28/25 4:15:40 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Aligos Therapeutics Inc.

      DEF 14A - Aligos Therapeutics, Inc. (0001799448) (Filer)

      4/28/25 4:05:31 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form PRE 14A filed by Aligos Therapeutics Inc.

      PRE 14A - Aligos Therapeutics, Inc. (0001799448) (Filer)

      4/16/25 4:01:43 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Aligos Therapeutics Inc.

      EFFECT - Aligos Therapeutics, Inc. (0001799448) (Filer)

      4/4/25 12:15:26 AM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B3 filed by Aligos Therapeutics Inc.

      424B3 - Aligos Therapeutics, Inc. (0001799448) (Filer)

      4/3/25 4:23:19 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-3 filed by Aligos Therapeutics Inc.

      S-3 - Aligos Therapeutics, Inc. (0001799448) (Filer)

      3/27/25 4:05:57 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Aligos Therapeutics Inc.

      SCHEDULE 13D/A - Aligos Therapeutics, Inc. (0001799448) (Subject)

      3/12/25 8:30:02 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by Aligos Therapeutics Inc.

      S-8 - Aligos Therapeutics, Inc. (0001799448) (Filer)

      3/10/25 4:01:58 PM ET
      $ALGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care